期刊文献+

辛伐他汀治疗急性冠脉综合征合并房颤的临床观察 被引量:3

Effect of simvastatin on acute coronary syndrome complicated with atrial fibrillation
在线阅读 下载PDF
导出
摘要 目的:探讨辛伐他汀对急性冠脉综合征合并阵发性房颤患者房颤再发率的影响。方法:将112例急性冠脉综合征合并阵发性房颤患者分为治疗组(60例),对照组(52例),两组患者均在急性冠脉综合征常规治疗基础上加用辛伐他汀40 mg/d,4周后改为20 mg/d,对照组为不规律口服辛伐他汀,口服辛伐他汀总时间少于8周;治疗组口服辛伐他汀总时间为12个月。追踪12个月,观察肝、肾功能,高敏C-反应蛋白、血脂、阵发性房颤再发率和转为持续性或永久性房颤的发生率,以及心血管事件的发生情况。结果:(1)对照组治疗前、后血脂和C-反应蛋白均无显著性变化(P>0.05);治疗组治疗前、后总胆固醇、低密度胆固醇和C-反应蛋白显著下降(P<0.05),高密度脂蛋白显著升高(P<0.05)。(2)阵发性房颤再发率和转为持续性(或永久性)房颤的发生率:治疗组发生6例(10%)明显低于对照组17例(36.5%)(P<0.05)。(3)心血管事件发生率:治疗组发生心血管事件8例(13.3%)明显低于对照组22例(42.3%)(P<0.05)。结论:辛伐他汀在治疗急性冠脉综合征合并心房颤动的过程中,在调节血脂同时,还具有抗房颤、减少心血管事件发生的作用。 Objective: To investigate the effect of simvastatin on acute coronary syndrome complicated with atrial fibrillation.Methods: A total of 112 cases with acute coronary syndrome complicated with atrial fibrillation were randomly divided into treatment group(60 cases) and control group(52 cases).Besides conventional treatment,simvastatin was used at 40 mg/d for 4 weeks,then 20 mg/d.Therapy of simvastatin was irregular in control group with total course less than 8 weeks,and the total course was 12 months.Hepal and renal function,high senstive C-reaction protein,blood lipid,reoccurrence of paroxysmal atrial fibrillation,incidence of sustained or permanent atrial fibrillation and status of cardiovascular diseases.Results: There was insignificant difference in blood lipid and C-reactive protein before and after treatment in control group(P〉0.05).After treatment,the levels of total cholesterol,low-density cholesterol and C-reactive protein were significantly decreased(P〈0.05),and high-density lipoprotein was significantly increased(P〈0.05) in treatment group.6 cases(10%) had reoccurrence of paroxysmal atri-al fibrillation or had paroxysmal transforming into sustained or permanent one in treatment group,which was significantly lower than control group(17/52,36.5%)(P〈0.05).And 8 cases had cardiovascular problem,significantly lower than control group(22/52,42.3%)(P〈0.05).Conclusion: Simvastatin can regulate blood lipid,anti-atrial fibrillation,and decrease the incidence of cardiovascular diseases.
作者 张英
出处 《海南医学院学报》 CAS 2010年第5期566-568,共3页 Journal of Hainan Medical University
基金 海南医学院科研基金资助学报项目(0020100150)~~
关键词 心房纤颤 急性冠脉综合征 辛伐他汀 心血管事件 Atrial fibrillation Acute coronary syndrome Simvastatin Cardiovascular incidence
  • 相关文献

参考文献11

二级参考文献57

  • 1商丽华,胡大一,赵秀丽,张仁汉.普伐他汀对快速起搏心房肌结构重构的影响[J].中华心律失常学杂志,2004,8(3):172-176. 被引量:21
  • 2李秀钧,罗梅,李军,王煜,王双,张敏,赵家伟,马凤海,邬云红,赵桂芝,张杰,周桥,傅茂.胰岛细胞与胰岛素抵抗[J].中华内分泌代谢杂志,2004,20(4). 被引量:8
  • 3王丽娟,项美香.他汀类药物与心律失常[J].国外医学(老年医学分册),2004,25(6):261-264. 被引量:1
  • 4李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2126
  • 5American diabetes association. Dyslipidemia management in adults with diabetes[ J ]. Diabetes Care, 2004, 27 (Suppl) : S68.
  • 6Worz C R, Bottorff M. Treating dyslipidemic patients with lipid modifying and combination therapies[J]. Pharrmcotherapy, 2003, 23(5): 625.
  • 7Snow V, Aronson M D, Hombake E R, et al. Lipid control in the managent of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians[J ]. Ann Intern Med, 2004, 140: 644.
  • 8Wierzbicki A S, Mikhailidis D P, Wray R, et al. Statin-fibrate combination: therapy for hyperlipidemia: a review[J]. Curr Med Res Opin, 2003, 19(3) : 155.
  • 9Fruchart J C. Peroxiisome proliferators-activatde recptor-alpha activation and high- density lipoprotein metabolism [ J ]. Am J Cardiol, 2001, 88(12A): 24N.
  • 10Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARa and induces HDL[J]. J Cin Invest, 2001 107: 1423.

共引文献83

同被引文献36

  • 1周烨,徐东杰,陈椿,杨兵,陈明龙,单其俊,曹克将,邹建刚.美托洛尔注射剂治疗快速房性心律失常的临床研究[J].中国心脏起搏与心电生理杂志,2007,21(2):128-131. 被引量:12
  • 2Carvalho P M,Silva N J,Dias P G.Glycogen Storage Disease type 1a-a secondary cause for hyperlipidemia:report of five cases[J].Journal of Diabetes and Metabolic Disorders,2013,12(1):25.
  • 3Polymeris A,Karoutsou E,Michalakis K.The impact of bariatric surgery procedures on type 2 diabetes,hyperlipidemia and hypertension[J].Hellenic J Cardio,2013,54(3):212.
  • 4Willard-Grace R,Devore D,Chen E H.The effectiveness of medical assistant health coaching for low-income patients with uncontrolled diabetes,hypertension,andhyperlipidemia:protocol for a randomized controlled trial and baseline characteristics of the study population[J].BMC Family Practice,2013,14(1):27.
  • 5KISHIMOTO M,SUGIYAMA T,OSAME K,et al.Eficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes[J].J Med Invest,2011,58:86.
  • 6GOLOMB B A,EVANS M A.Statin adverse effects:a review of the literature and evidence for a mitochondrial mechanism[J].Am J Cardiovasc Drugs,2008,8:373.
  • 7Farnier M,Averna M,Missault L,et al.Lipid-altering efficacy of ezetimibe/simv-astatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy-The IN-CROSS study[J].International Journal of Clinical Practice,2009,(04):547.
  • 8Pearson T A,Ballantyne C M,Veltri E,et al.Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of Ezetimibe monotherapy or Ezetimibe added to baseline statin therapy[J].American Journal of Cardiology,2009,(03):369.
  • 9Chenot F,Montant P F,Marcovitch O.Co-administration of ezetimibe and simvastatin in acute rnyocardial infarction[J].European Journal of Clinical Investigation,2007,(05):357.
  • 10Pearson T A,Ballantyne C M,Veltri E.Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of Ezetimibe monotherapy or Ezetimibe added to baseline statin therapy[J].American Journal of Cardiology,2009,(03):369.

引证文献3

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部